Sydney Jennings

Dupilumab is the first targeted treatment for B to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.

The investigational dual GLP-1/GLP-2 agonist led to 11.6% weight loss over 28 weeks with no lifestyle changes, showing strong safety and tolerability in the trial.

Your daily dose of the clinical news you may have missed.

RAD 2025: Expert insights on the psychosocial burden of AD, flexible dosing, and cross-specialty collaboration in pediatric care.

RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.

Your daily dose of the clinical news you may have missed.

The FDA cleared Happy Ring, a wearable device for at-home diagnosis of sleep disorders, enhancing access to vital sleep health solutions.

Your daily dose of the clinical news you may have missed.

Johann Gudjonsson, MD, discusses how OX-40/OX-40L signaling drives immune activation in AD and its emerging role as a genetic and therapeutic target.

Research presented at ACOG 2025 showed 99% of pregnant women included in the analysis were eligible for aspirin, per ACOG guidelines.

RAD 2025: Peter Lio, MD, discussed the benefits of disease-specific meetings, the evolving AD landscape, and why continuity across sessions enhances clinician education.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.

EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.

Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.

Your daily dose of the clinical news you may have missed.

At RAD 2025, pediatric dermatologist Elizabeth Swanson, MD, discussed the value of focused AD education and anticipated label expansions for several treatments.

FDA-cleared DermaSensor device shows 96% sensitivity and reduces missed skin cancer diagnoses by 50% in primary care, according to new data.

At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.

Valid and accessible measures are needed to monitor low-value care practices and set benchmarks for de-implementation efforts, researchers reported.

Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.

RAD 2025. Peter Lio, MD, shares details from his presentation on shared decision making when treating children with atopic dermatitis.

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

RAD 2025: Jiade Yu, MD, discussed chronic hand eczema as a distinct condition from AD, highlighting its clinical burden and emerging treatments, such as delgocitinib.

Arcutis Biotherapeutics announced today the enrollment of the first patient in the phase 2 INTEGUMENT-INFANT trial.

From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed at ACOG 2025.

RAD 2025: Explore expert insights on chronic hand eczema, its differences from atopic dermatitis, and emerging treatments in this informative video series.

RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.

RAD 2025: Lisa Swanson, MD, shares insights on pediatric atopic dermatitis, addressing questions from both a dermatologist's and an allergist's perspective.

Dupilumab monotherapy showed significant improvements in atopic dermatitis symptoms in patients with skin of color, according to late-breaking data presented at RAD 2025.

RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.